These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33981224)

  • 1. Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer.
    Liu Y; Wang C; Li J; Zhu J; Zhao C; Xu H
    Front Pharmacol; 2021; 12():633453. PubMed ID: 33981224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.
    Liu Y; Cao M; Cai Y; Li X; Zhao C; Cui R
    Front Cell Dev Biol; 2020; 8():95. PubMed ID: 32154250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
    Hu L; Cong L
    Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
    Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
    Gao L; Shay C; Lv F; Wang X; Teng Y
    Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
    Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
    Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
    Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
    Lang L; Teng Y
    Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
    Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H; Alem Glison DM; Kim RD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma.
    Shin JY; Ahn SM
    J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF19-
    Raja A; Park I; Haq F; Ahn SM
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z; Cui Y; Xu X; Han T
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
    Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
    Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
    Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
    Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.